Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMAB818 vs Lucentis in Wet Age-related Macular Degeneration
NCT04884399Phase 1Completed
- Sponsor
- Shanghai Biomabs Pharmaceuticals
- Start
- Jun 2021
- Primary completion
- Dec 2022
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CKD-701 in exudative macular degeneration (2 arms), sponsored by Shanghai Biomabs Pharmaceuticals. Primary endpoint: Number of Participants With Adverse Events That Are Related to Treatment. Started Jun 2021; status: completed.
02
Drugs
CKD-701
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT04884399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04884399.